Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)

Summary

This is a multicenter, open-label trial to evaluate the efficacy and safety of AXS-07 in subjects with migraine attacks and prior inadequate response to oral CGRP inhibitors.

Timeline

Start

2022-08-31

Primary completion

2024-11-27

Completion

2024-11-27

Outcome

Met primary endpoint

release “today announced that the EMERGE Phase 3 trial of SYMBRAVO ® (MoSEIC™ meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP inhibitors met its primary endpoint” gcs-web.com ↗

release “EMERGE Phase 3 trial of SYMBRAVO ® (MoSEIC™ meloxicam and rizatriptan) in patients experiencing inadequate response to oral CGRP inhibitors met its primary endpoint” gcs-web.com ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Meloxicam	Small molecule	—	Oral
Subject	rizatriptan	Unknown	—	Oral

Indications